The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME
申请人:Dana Farber Cancer Institute, Inc.
公开号:EP3778604A1
公开(公告)日:2021-02-17
Compounds having the formula I, II, or III:
are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.
具有式 I、II 或 III 的化合物:
的化合物。本公开的化合物可用于治疗神经退行性疾病,如帕金森病。
LRRK2 inhibitors and methods of making and using the same
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US10913744B2
公开(公告)日:2021-02-09
Compounds having the formula I, II, or III:
are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.
具有式 I、II 或 III 的化合物:
的化合物。本公开的化合物可用于治疗神经退行性疾病,如帕金森病。
EGFR Inhibitors and Methods of Treating Disorders
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US20190040065A1
公开(公告)日:2019-02-07
The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.